In a report released today, Harshita Polishetty from B.Riley FBR reiterated a Buy rating on Agenus Inc (AGEN – Research Report), with a price target of $5. The company’s shares closed last Monday at $2.73.
“Agenus (AGEN) highlighted that it recently triggered the interim analysis for its CTLA-4-PD-1 combination and PD-1 monotherapy trials in patients with second-line cervical cancer on its earnings call last week (8/9), with data expected at a major medical conference later this year. The company remains on track to file regulatory submissions in 2H20, with the potential to file even earlier. We look forward to these data readouts, which could serve as catalysts for AGEN shares and validate the company’s platform. We reiterate our Buy rating and $5 PT.”
According to TipRanks.com, Polishetty is a 4-star analyst with an average return of 29.3% and a 59.1% success rate. Polishetty covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Karyopharm Therapeutics, and Mirati Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Agenus Inc with a $5 average price target.
The company has a one-year high of $3.88 and a one-year low of $1.54. Currently, Agenus Inc has an average volume of 991.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon.